Moreover, there is a group of GBM patients with a mutation at the R132 residue of isocitrate dehydrogenase 1 (IDH1), giving rise to a neoenzyme, which produces the oncometabolite 2-hydroxyglutarate (2-HG) from α-KG. This evidence concerns the gene IDH1 and glioblastoma.